Introduction
============

Lung cancer remains one of the most common malignancies and leading causes of cancer-related mortality both in China and worldwide ([@b1-ol-0-0-7016],[@b2-ol-0-0-7016]). Approximately 80--85% of lung cancers are non-small cell lung cancer ([@b3-ol-0-0-7016]). In recent years, huge progress had been made in the treatment of non-small cell lung cancer (NSCLC) patients harboring *EGFR* mutation and *ALK* rearrangement ([@b4-ol-0-0-7016]--[@b7-ol-0-0-7016]). However, effective therapy specifically targeting *KRAS* mutation, which accounts for 25--50% of NSCLC patients in white populations and 5--10% in Asian populations, has not been developed yet ([@b8-ol-0-0-7016]--[@b11-ol-0-0-7016]).

*KRAS* is a member of the *Ras* gene family, which encodes small G proteins with intrinsic GTPase activity, contributing to activation of downstream effectors involved in multiple pathways including apoptosis, proliferation and differentiation ([@b8-ol-0-0-7016],[@b12-ol-0-0-7016],[@b13-ol-0-0-7016]). Point mutations occurred in tumors result in the loss of intrinsic GTPase activity and consequently in the deregulation of cell proliferation signals ([@b13-ol-0-0-7016],[@b14-ol-0-0-7016]). *KRAS* mutation occurs mainly in codon 12, 13 or 61. Most common types of *KRAS* mutation are G12C, G12V, and G12D ([@b8-ol-0-0-7016],[@b9-ol-0-0-7016]). In addition, *in vitro* data reported by Garassino *et al* suggested that NSCLC cell lines harboring a G12C, G12V or G12D *KRAS* mutation had differential sensitivity to chemotherapeutic agents ([@b15-ol-0-0-7016]). It appears that various types of *KRAS* mutations differ in clinical characters and drug response ([@b16-ol-0-0-7016],[@b17-ol-0-0-7016]).

As early as 1990, *KRAS* mutation was already described as a negative prognostic marker for both overall survival (OS) and disease-free survival in lung cancer ([@b18-ol-0-0-7016]). Not until the last decades, more and more attention has been paid to the clinical significance of *KRAS* mutation in NSCLC. When it comes to the first-line platinum-based chemotherapy for advanced NSCLC patients, some researchers tend to believe there is no difference between *KRAS* mutant and wild-type patients regarding therapeutic response and prognosis ([@b14-ol-0-0-7016],[@b19-ol-0-0-7016],[@b20-ol-0-0-7016]). However, there were several studies indicated that *KRAS* mutation was a predictive factor of worse progression-free survival (PFS) or OS in advanced NSCLC patients treated with platinum-based chemotherapy ([@b21-ol-0-0-7016]--[@b24-ol-0-0-7016]). Considering the discrepant role of *KRAS* and its subtypes on effect of chemotherapy, the aim of this study was to investigate the predictive significance of *KRAS* mutation and its subtypes on clinical response and PFS in advanced NSCLC patients treated with first-line platinum-based chemotherapy.

Materials and methods
=====================

### Study design

In this retrospective study, patients received *KRAS* mutation detection between August 2014 and June 2016 at Shanghai Pulmonary Hospital affiliated to Tongji University School of Medicine were included. We retrospectively reviewed patients\' medical records to evaluate clinicopathological features and treatment regimens. All eligible patients\' clinical data including age, sex, smoking status, histological type, TNM stage, Eastern Cooperative Oncology Group (ECOG) performance status (PS), treatment regimens, response to treatment, date of first diagnosis, date of starting chemotherapy, and date of disease progression or date of last contact. Pathological diagnosis was made by pathologists. Staging was carried out according to the staging system of the 2009 International Association for the Study of Lung Cancer (version 7) ([@b25-ol-0-0-7016]). Nonsmokers were defined as patients with the smoking dose of \<100 cigarettes in their lifetime. Clinical response was evaluated by at least two clinicians according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 ([@b26-ol-0-0-7016]). Inclusion criteria were: Adult (age≥18 years old) patients; recurrent or IIIB/IV NSCLC patients; patients received first-line platinum-based chemotherapy. Exclusion criteria were: Unknown mutational status; detected *EGFR* mutation or *ALK* rearrangement; no complete documentation; no response evaluation; adjuvant chemotherapy or radiochemotherapy. The study was approved by the Ethics Committees of Shanghai Pulmonary Hospital. Informed consent was obtained from all individual participants included in the present study. This study was conducted according to the Declaration of Helsinki, 7th version.

### KRAS mutation analysis

Total DNA was extracted from tissue samples using AmoyDx DNA kit (Amoy Diagnostics Co., Ltd., Xiamen, China). The quality and quantity of extracted DNA were measured by NanoDrop 2000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). *KRAS* mutation was identified by an AmoyDx^®^ Human *KRAS* gene 7 Mutations Fluorescence Polymerase Chain Reaction (PCR) Diagnostic kit (Amoy Diagnostics Co., Ltd.). The real-time PCR conditions were as previously described ([@b27-ol-0-0-7016]--[@b29-ol-0-0-7016]). β-actin was used as an internal reference gene to ensure the quality of the extracted DNA and *KRAS* mutant DNA was used as positive control.

### Statistical analysis

The relation between categorical parameters was tested using Pearson\'s χ^2^ test (Fishers exact test was used when n≤5). Kaplan-Meier curve was used to estimate the distribution of survival and log-rank test was used to analyze differences between groups. PFS was defined as the first day of treatment until either tumor progression or death. We used cox proportional hazards models for univariate and multivariate analysis to estimate clinicopathological features, *KRAS* mutation types and treatment regimens for their associations with PFS. Independent variables with P\<0.10 in the univariate analysis were enrolled in multivariate analysis. P-values \<0.05 were defined statistically significant. Confidence intervals were calculated at a 95% CI. Statistical tests were carried out using SPSS 20.0 software (IBM Corporation, Armonk, NY, USA).

Results
=======

### Patient characteristics

In total, 2,183 patients received *KRAS* mutation detection at Shanghai Pulmonary Hospital between August 2014 and June 2016 were enrolled into this study and 218 (10.0%) cases harbored *KRAS* mutation. Distribution of different types of *KRAS* mutation found within 218 patients are listed in [Fig. 1](#f1-ol-0-0-7016){ref-type="fig"}. Three most common *KRAS* mutations were G12C (32.1%), G12D (23.4%) and G12V (21.1%). Other codon 12 mutations including G12A (12.8%), G12S (4.1%) and G12R (1.4%) were found in 20% of the patients. 3 patients had codon 13 G13D mutation. Four types of double mutations were found in 8 patients: G12C + G12R (4 patients), G12C + G12V (2 patients), G12D + G12V (1 patient) and G12A + G12V (1 patient). Based on our inclusion and exclusion criteria, we further analyzed 100 EGFR/ALK/*KRAS* wild-type and 70 *KRAS* mutant patients. The median age of whole study group was 61 years old (range 28--78). In total, 84.1% of patients were stage IV disease at diagnosis, and 77.6% of patients displayed histology of adenocarcinoma. The patient characteristics were listed in [Table I](#tI-ol-0-0-7016){ref-type="table"}. The patient basic characteristics were well-matched between *KRAS* mutant and wild-type groups except for sex (P=0.035). As for the treatment regimens, 74.1% of all patients received first-line chemotherapy with carboplatin-based chemotherapy, with a higher percentage of wild-type *KRAS* patients (78.0%) receiving carboplatin-based doublet comparing with mutant *KRAS* patients (68.6%). Numerically more *KRAS* mutant patients received a cisplatin-based chemotherapy when compared with *KRAS* wild-type patients (28.6% vs. 21.0%, respectively). However, there seems to be more patients in the *KRAS* wild-type group received platinum/pemetrexed treatments (68.0% in *KRAS* wild-type group vs. 57.1% in *KRAS* mutant group). Whereas patients with wild-type *KRAS* were as likely as patients with mutant *KRAS* to receive platinum/gemcitabine chemotherapies. Of note, 6 patients within the *KRAS* mutant group received platinum/docetaxel whereas only 1 patient within the *KRAS* wild-type group received platinum/docetaxel treatments.

### Effect of KRAS mutation on response rate and PFS

None of the patients reached complete response. Partial response was similar between two groups (21.4% in *KRAS* mutant patients vs. 19.0% in *KRAS* wild-type patients). Comparatively, stable disease was observed more in wild-type *KRAS* patients than in mutant *KRAS* patients (67.0% vs. 44.3%, respectively). However, numerically more disease progressed in patients with mutant *KRAS* than wild-type *KRAS* (34.3% vs. 14.0%). There were no statistically significant differences in the objective response rate (ORR). In contrast, disease control rate (DCR) of *KRAS* wild-type patients to platinum-based chemotherapy was obviously higher than *KRAS* mutant patients (86.0% vs. 65.7%, P=0.002; [Table II](#tII-ol-0-0-7016){ref-type="table"}). In [Table II](#tII-ol-0-0-7016){ref-type="table"}, we also listed clinical outcomes of three most common *KRAS* mutation subtypes and other rare mutations. Among them, although G12V has the lowest DCR for 55.6%, response to platinum-based chemotherapy had no statistically significant differences between mutation subtypes.

A total of 140 (82.4%) patients had progressed disease during the study period, with a median PFS for all subjects of 5.9 months (95% CI, 4.9--6.9 months). In all included patients with metastatic NSCLC at diagnosis, PFS was shorter in the *KRAS* mutant group vs. wild-type group (4.2 vs. 6.3 months; P=0.007; [Fig. 2A](#f2-ol-0-0-7016){ref-type="fig"}). In addition, there was a shorter but only marginally statistically significant PFS in *KRAS* mutant patients with adenocarcinoma histology patients (4.3 months vs. 6.7 months; P=0.051; [Fig. 2B](#f2-ol-0-0-7016){ref-type="fig"}). It suggested that the presence of *KRAS* mutation may be associated with a worse response to first-line platinum-based chemotherapy in advanced NSCLC patients. Next, we compared PFS of wild-type *KRAS* patients with three most common *KRAS* subtypes G12V, G12C, G12D and other rare mutations. When comparing patients with G12V mutant vs. wild-type, there was a statistically significant shorter PFS (2.9 months and 6.4 months, respectively; P=0.001). While other *KRAS* subtypes had no differences in PFS compared with wild-type *KRAS* ([Fig. 2C](#f2-ol-0-0-7016){ref-type="fig"}). Patients with *KRAS* G12V mutation had inferior PFS compared with patients with non-G12V mutation (median PFS, 2.9 vs. 4.7 months; P=0.045; [Fig. 3B](#f3-ol-0-0-7016){ref-type="fig"}). When comparing patients with G12C vs. non-G12C mutation and patients with G12D vs. non-G12D mutation, there was no differences in PFS, 4.4 months (95% CI, 3.3--5.5) vs. 4.2 months (95% CI, 2.3--6.1; P=0.202; [Fig. 3A](#f3-ol-0-0-7016){ref-type="fig"}) and 7.0 months (95% CI, 1.1--12.8) vs. 4.3 months (95% CI, 3.8--4.8; P=0.519; [Fig. 3C](#f3-ol-0-0-7016){ref-type="fig"}). It suggested that response to chemotherapy is not the same among *KRAS* mutation subtypes and patients with *KRAS* G12V mutation showed the poorest PFS than those with other *KRAS* mutant types.

### Univariate and multivariate analysis

In univariate analysis, sex, smoking history and *KRAS* G12V mutation were significantly associated with PFS. Women had decreased risk of progressed disease when compared with men (HR, 0.616; 95% CI, 0.405--0.937; P=0.024). Smoking history also affected PFS (never smokers vs. current/former smokers; HR,0.665; 95% CI, 0.472--0.937; P=0.020). *KRAS* G12V was associated with shorter PFS (HR, 2.342; 95% CI, 1.378--3.981; P=0.002). In multivariate analysis, only *KRAS* G12V mutation was associated with shorter PFS (HR, 2.116; 95% CI, 1.211--3.696; P=0.008; [Table III](#tIII-ol-0-0-7016){ref-type="table"}).

In *KRAS* mutant group, univariate analysis showed that smoking history did not have impact on outcome for PFS (HR, 0.799; 95% CI, 0.462--1.379; P=0.420). And there was marginally statistic difference in outcome of G12V mutant patients vs. other mutant *KRAS* patients in univariate analysis (HR, 1.762; 95% CI, 0.992--3.129; P=0.053). In multivariate analysis based on age, G12V mutation status and cisplatin- or carboplatin-based chemotherapy, results showed that G12V mutant patients did have a shorter PFS than other *KRAS* mutant types (HR, 1.831; 95% CI, 1.025--3.270; P=0.041; [Table III](#tIII-ol-0-0-7016){ref-type="table"}).

Discussion
==========

Our treatment of NSCLC has been dramatically improved with the introduction of molecular markers. Targeted therapies, including tyrosine kinase inhibitors (TKIs), for *EGFR* mutation and *ALK* rearrangement improved PFS in patients bearing the relevant mutations ([@b4-ol-0-0-7016],[@b7-ol-0-0-7016],[@b30-ol-0-0-7016]). However, effective therapy specifically targeting *KRAS* mutation has not been developed yet. For patients with *KRAS* mutation, platinum-based chemotherapy remains their first choice. Nevertheless, the predictive value of KRAS mutation in NSCLC for chemotherapy also remains unclear.

In the last decades, although a large number of studies had been conducted focusing on *KRAS* mutation, the prognostic and predictive value of *KRAS* in lung cancer is still a highly debated issue. Considering the enormous discrepancy of studies in terms of races, tumor stage, histological types and various treatments, it is difficult to draw a definite conclusion. Therefore, we analyzed a well-defined Chinese patient cohort with advanced NSCLC received first-line platinum-based chemotherapy in our study. *KRAS* mutation rate in all tested population was 10.0%, which is in accordance with other studies of Asian NSCLC study cohort ([@b10-ol-0-0-7016],[@b11-ol-0-0-7016],[@b29-ol-0-0-7016],[@b31-ol-0-0-7016],[@b32-ol-0-0-7016]). Furthermore, we found a ratio of the major subtypes, G12C (32.1%), G12V (23.4%), G12D (21.1%), which is almost identical with the previous reports ([@b31-ol-0-0-7016]--[@b35-ol-0-0-7016]). We also identified four kinds of co-mutations in our study group: Four patients with G12C/G12R, two patients with G12C/G12V, one patient with G12D/G12V and one patient with G12A/G12V. And no significant differences in PFS between *KRAS* co-mutant and other KRAS mutant or wild-type patients were found (data not shown).

Prior findings indicated patients with *KRAS* mutation were preferably to be smokers and have histology of adenocarcinoma comparing with patients of wild-type *KRAS* ([@b36-ol-0-0-7016],[@b37-ol-0-0-7016]). However, in the current study, we noted that there were no differences in smoking history and pathological types between two groups of patients. Nevertheless, we observed *KRAS* mutation was not exclusively found in patients with adenocarcinoma. Hence testing all patients with NSCLC for *KRAS* mutation is necessary. Although *KRAS* mutant patients and *KRAS* wild-type patients shared similar smoking habits, smokers had increased risk of shorter PFS compared with non-smoker in our univariate analysis of whole study group. There seemed to be more males in the *KRAS*-mutant group comparing with the group of patients with wild-type *KRAS*. But the significance of this finding was complicated to explain regarding clinical outcome. Although male sex was dramatically associated with worse outcomes in our univariate analysis, survival was similar in whole study group between *KRAS* mutant and wild-type groups despite the *KRAS* cohort had a higher percentage of males. The majority of patients in the study group received a cisplatin or carboplatin plus pemetrexed or gemcitabine chemotherapy. The different choice of chemotherapy regimens did not affect the PFS both in whole group and in *KRAS* mutant cohort in univariate and multivariate analysis.

There were many articles reporting inconsistent results in regards to the impact of *KRAS* mutation on survival of advanced NSCLC patients who received platinum-based chemotherapy. For example, a retrospective analysis performed by Mellema *et al* showed no significant differences in clinical response to chemotherapy or OS when compared patients with *KRAS* mutation with patients without *KRAS* mutation ([@b19-ol-0-0-7016]). Conversely, Metro *et al* demonstrated that patients with *KRAS* mutation had lower response rates, and shorter PFS compared with *EGFR* wild-type/*KRAS* wild-type patients ([@b23-ol-0-0-7016]). Besides, Hames *et al* reported that the presence of *KRAS* mutation in advanced NSCLC patients displayed a worse prognosis of platinum-based chemotherapy compared with those absence of detectable driver mutations ([@b21-ol-0-0-7016]). In the current analysis, our results suggested that *KRAS* mutant patients did have lower DCR compared with *KRAS* wild-type patients, but not ORR. In addition, *KRAS* mutant patients demonstrated a decrease PFS comparing with wild-type patients, which was in accordance with prior report ([@b21-ol-0-0-7016]) and we found more convincing results in patients with metastatic NSCLC at diagnosis, PFS was significantly shorter in the *KRAS* mutant group vs. wild-type group (4.2 vs. 6.3 months; P=0.007). In addition, there was a shorter but only marginally statistically significant PFS in *KRAS* mutant patients with adenocarcinoma histology patients (4.3 months vs. 6.7 months; P=0.051). Based on the above results, we made the conclusion that KRAS mutation was a negative predictive factor of PFS in Chinese patients with advanced NSCLC received first platinum-based chemotherapy. Admittedly, this study was conducted at a single institution and had limited patient samples. We considered that, to make our findings more convincing, sharing of more data from multicenter studies, especially those covering various populations should be encouraged. We will also stay focuced on this issue and further exploration of the prognostic value of *KRAS* and its underlying mechanism is needed. Although recent research in colorectal cancer reported that G12V mutation demonstrated poor response to therapy and survival ([@b38-ol-0-0-7016]), the relevance of specific mutation subtypes in *KRAS* and clinical outcome remains controversial in NSCLC ([@b16-ol-0-0-7016],[@b39-ol-0-0-7016]--[@b41-ol-0-0-7016]). In recent studies of advanced NSCLC, effects of *KRAS* G12V mutation regrading as either response to chemotherapy or OS were not obvious ([@b40-ol-0-0-7016]). However, in our study, patients with G12V mutant not only responded poorer to platinum-based chemotherapy, although not statisticly significant, but also had a significantly shorter PFS than those with other *KRAS* mutations. Our finding was in accordance with results carried out by Ihle *et al* ([@b16-ol-0-0-7016]). Downstream signaling of *RAS* differed in mutation subtypes. *KRAS* G12C/G12V preferably activated RalA/B signaling while *KRAS* G12D activated Akt pathway and the former demonstrated decreased survival ([@b42-ol-0-0-7016]). Taking all our presented results together, there is reason to believe that, in NSCLC, patients with different *KRAS* mutant subtypes may lead to distinct response to first-line platinum-based chemotherapy. Furthermore, subtype-specific mutation analysis is necessary in clinical practice, which may help to identify the most effective treatment regimens for each individual patient. Despite some of our results were consistent with previous publication, our study was conducted among Chinese population. Considering the differences in gene background between Caucasian and East Asian people ([@b43-ol-0-0-7016],[@b44-ol-0-0-7016]), whether previous observation is also true among East Asian population remains uncertain. The conclusions we made in the study will provide clinicians with more comprehensive evidence when making clinical decisions for NSCLC patients with *KRAS* mutation.

There are several limitations in the present study that should be acknowledged. First of all, selection bias was inevitable due to the nature of retrospective studies. Second this study design was at a single institution. Taking the high cost of molecular detection into consideration, not all patients in our hospital received *KRAS* mutation test, therefore patients included in our study may not be representative of a general population. Sufficiency of cancer samples was also one of the limitations in this study. However, according to previous reports, in white populations KRAS accounts for 25--50% of NSCLC patients but KRAS mutations are only found in 5--10% of NSCLC patients in Asian populations ([@b8-ol-0-0-7016]--[@b11-ol-0-0-7016]). When we reviewed relative studies conducted among Caucasian populations, we found our patient number was very similar to other studies. In a retrospective analysis performed by Hames *et al* and colleagues, they compared 70 patients with pan-mutation negative and 80 patients with KRAS-mutant advanced NSCLC patients ([@b21-ol-0-0-7016]). On the other hand, considering the lower incidence of KRAS mutation among Asian people, we only focused on whether KRAS mutation was a negative predictive factor of PFS in Chinese patients with advanced NSCLC received first platinum-based chemotherapy. Further studies should be done aiming at the prognostic value of *KRAS* mutation on chemotherapy and also comparing responses with different cytotoxic chemotherapy regimens in patients with advanced NSCLC based on *KRAS* mutation and subtypes. Thus, considering the above limitations, multi-centered, international cooperative and larger number of NSCLC patients should be analyzed to valid our present findings.

The current study suggested that the presence of *KRAS* mutation was associated with a worse response in advanced NSCLC patients received first-line platinum-based chemotherapy. Responses to cytotoxic chemotherapy are not same among *KRAS* mutation subtypes. As the currently available literatures are still conflicting on the predictive value of *KRAS* mutation and its subtypes in advanced NSCLC, future studies should be done aiming at comparing responses with different cytotoxic chemotherapy regimens in patients with advanced NSCLC based on *KRAS* mutation and subtypes.

The present study was supported by grants from the National Natural Science Foundation of China (nos. 81372392 and 81402486) and Shanghai Committee of Science and Technology, China (no. 134119b1001).
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###### 

Patient characteristics.

                                     *KRAS* mutant (n=70)   *KRAS* wild-type (n=100)   P-value
  ---------------------------------- ---------------------- -------------------------- ---------
  Mean age at diagnosis, mean ± SD   61±7.34                60±9.31                    0.334
  Sex, n (%)                                                                           
    Male                             60 (85.7)              72 (72.0)                  0.035
    Female                           10 (14.3)              28 (28.0)                  
  Smoking history, n (%)                                                               0.302
    Smoker                           42 (60.0)              52 (52.0)                  
    Non-smoker                       28 (40.0)              48 (48.0)                  
  Histology, n (%)                                                                     0.826
    Adenocarcinoma                   55 (78.6)              77 (77.0)                  
    Squamous                         6 (8.6)                12 (12.0)                  
    Other                            0 (0.0)                1 (1.0)                    
    NSCLC-NOS                        9 (12.9)               10 (10.0)                  
  Stage, n (%)                                                                         
    IIIB                             6 (8.6)                12 (12.0)                  0.475
    IV                               64 (91.4)              88 (88.0)                  
  Platinum, n (%)                                                                      
    Cisplatin                        20 (28.6)              21 (21.0)                  0.287
    Carboplatin                      48 (68.6)              78 (78.0)                  
    Other                            2 (2.9)                1 (1.0)                    
  Platinum doublets, n (%)                                                             
    Platinum/pemetrexed              40 (57.1)              68 (68.0)                  0.029
    Platinum/gemcitabine             23 (32.9)              31 (31.0)                  
    Platinum/docetaxel               6 (8.6)                1 (1.0)                    
    Other                            1 (1.4)                0 (0.0)                    

P-value based on Kruskal-Wallis test, otherwise P-value based on χ^2^ test or Fisher\'s exact test. NSCLC-NOS, non-small cell lung cancer-not otherwise specified; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

###### 

Response to first line chemotherapy in *KRAS* mutant vs. *KRAS* wild-type NSCLC patients.

                     *KRAS* mutant (n=70)                                           
  ---------- ------- ---------------------- ------- ------- ------- ------- ------- -------
  Response                                                                          
    CR       --      --                     --      --      --      --              
    PR       19      15                     6       4       1       4               
    SD       67      31                     12      6       5       8               
    PD       14      24                     5       8       3       8               
  ORR        19.0%   21.4%                  26.1%   22.2%   11.1%   20.0%   0.893   0.697
  DCR        86.0%   65.7%                  78.3%   55.6%   66.7%   60.0%   0.442   0.002

P-value was calculated among KRAS mutation subtypes.

P-value was calculated between *KRAS* wild-type and mutated patients. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; ORR, objective response rate; DCR, disease control rate.

###### 

Prognostic evaluation of clinical and histopathological characteristics in whole group and in *KRAS* mutant subgroup- progression free survival.

  Variable                       Univariate analyses 1^[a](#tfn5-ol-0-0-7016){ref-type="table-fn"}^ HR (95% CI) P-value   Multivariate analyses 1^[a](#tfn5-ol-0-0-7016){ref-type="table-fn"}^ HR (95% CI) P-value   Univariate analyses 1^[b](#tfn6-ol-0-0-7016){ref-type="table-fn"}^ HR (95% CI) P-value   Multivariate analyses 1^[b](#tfn6-ol-0-0-7016){ref-type="table-fn"}^ HR (95% CI) P-value
  ------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  Age, \<61 vs. ≥61 years old    1.170 (0.837--1.634)                                                                                                                                                                1.622 (0.952--2.746)                                                                     --
                                 0.359                                                                                                                                                                               0.075                                                                                    0.121
  Sex, female vs. male           0.616 (0.405--0.937)                                                                                                                                                                0.844 (0.399--1.784)                                                                     
                                 0.024                                                                                                                                                                               0.657                                                                                    
  Stage, IIIB/recurrent vs. IV   0.811 (0.457--1.438)                                                                                                                                                                0.781 (0.259--1.990)                                                                     
                                 0.473                                                                                                                                                                               0.525                                                                                    
  Smoking, never                 0.665 (0.472--0.937)                                                                     --                                                                                         0.799 (0.462--1.379)                                                                     
  vs. current/former             0.020                                                                                    0.126                                                                                      0.420                                                                                    
  Pathology, SQC                 1.301 (0.775--2.183)                                                                                                                                                                0.779 (0.306--1.981)                                                                     
  vs. ADC                        0.319                                                                                                                                                                               0.599                                                                                    
  KRAS, mutant vs. wt            1.324 (0.942--1.861)                                                                                                                                                                --                                                                                       
                                 0.106                                                                                                                                                                                                                                                                        
    G12C vs. wt                  1.107 (0.654--1.873)                                                                                                                                                                --                                                                                       
                                 0.705                                                                                                                                                                                                                                                                        
    G12V vs. wt                  2.342 (1.378--3.981)                                                                     2.116 (1.211--3.696)                                                                       --                                                                                       
                                 0.002                                                                                    0.008                                                                                                                                                                               
    G12D vs. wt                  1.031 (0.474--2.239)                                                                                                                                                                --                                                                                       
                                 0.939                                                                                                                                                                                                                                                                        
    G12C vs. others              --                                                                                                                                                                                  0.697 (0.395--1.231)                                                                     
                                                                                                                                                                                                                     0.214                                                                                    
    G12V vs. others              --                                                                                                                                                                                  1.762 (0.992--3.129)                                                                     1.831 (1.025--3.270)
                                                                                                                                                                                                                     0.053                                                                                    0.041
    G12D vs. others              --                                                                                                                                                                                  0.774 (0.350--1.714)                                                                     
                                                                                                                                                                                                                     0.528                                                                                    
  Chemotherapy, cisplatin        1.296 (0.883--1.902)                                                                                                                                                                1.720 (0.982--3.013)                                                                     --
  vs. carboplatin                0.186                                                                                                                                                                               0.058                                                                                    0.158
  Chemotherapy, gemcitabine      1.390 (0.971--1.991)                                                                     --                                                                                         1.527 (0.852--2.736)                                                                     
  vs. pemetrexed                 0.072                                                                                    0.335                                                                                      0.155                                                                                    

Independent variables with P\<0.10 in the univariate analyses were included in the model

Univariate and multivariate analysis for PFS in all patients after first line platinum-based chemotherapy

Univariate and multivariate analysis for PFS in *KRAS* mutated patients after first line platinum-based chemotherapy. PFS, progression-free survival HR, hazard ratio; CI, confidence interval; Cox\'s model, multivariate analyses with forward elimination; wt, wild-type.
